EcoDrugPlus

Sodium Channel Epithelial 1 Subunit Beta

Ensembl ID : ENSUAMG00000016767
Gene Symbol: SCNN1B
2 Cross references
151 Possible Orthologues:

Sodium Channel Epithelial 1 Subunit Gamma

Ensembl ID : ENSUAMG00000016751
Gene Symbol: SCNN1G
2 Cross references
155 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 10

Ensembl ID : ENSUAMG00000006396
Gene Symbol: SCN10A
2 Cross references
297 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 3

Ensembl ID : ENSUAMG00000026151
Gene Symbol: SCN3A
2 Cross references
167 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 4

Ensembl ID : ENSUAMG00000007431
Gene Symbol: SCN4A
2 Cross references
193 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 5

Ensembl ID : ENSUAMG00000006270
Gene Symbol: SCN5A
2 Cross references
94 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 8

Ensembl ID : ENSUAMG00000008973
Gene Symbol: SCN8A
2 Cross references
274 Possible Orthologues:

Solute Carrier Family 10 Member 2

Ensembl ID : ENSUAMG00000016521
Gene Symbol: SLC10A2
2 Cross references
214 Possible Orthologues:

Solute Carrier Family 22 Member 11

Ensembl ID : ENSUAMG00000023337
Gene Symbol: SLC22A11
2 Cross references
885 Possible Orthologues:

Solute Carrier Family 22 Member 12

Ensembl ID : ENSUAMG00000023336
Gene Symbol: SLC22A12
2 Cross references
470 Possible Orthologues:

Solute Carrier Family 22 Member 6

Ensembl ID : ENSUAMG00000017121
Gene Symbol: SLC22A6
2 Cross references
490 Possible Orthologues:

Solute Carrier Family 22 Member 8

Ensembl ID : ENSUAMG00000017118
Gene Symbol: SLC22A8
2 Cross references
310 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).